Androgenic Alopecia - Pipeline Review, H2 2016 - Companies Mentioned Includes Allergan, Aclaris Therapeutics, Almirall, Histogen & Samumed LLC - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Androgenic Alopecia - Pipeline Review, H2 2016" report to their offering.

Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

This report provides comprehensive information on the therapeutic development for Androgeneic alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Androgeneic alopecia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Aclaris Therapeutics Inc
  • Allergan Plc
  • Almirall SA
  • BiologicsMD Inc
  • Dong-A Socio Holdings Co Ltd
  • Histogen Inc
  • RepliCel Life Sciences Inc
  • RiverTown Therapeutics Inc
  • Samumed LLC
  • Sucampo Pharmaceuticals Inc
  • SWITCH Biotech LLC

Key Topics Covered:

  1. Introduction
  2. Androgeneic alopecia Overview
  3. Therapeutics Development
  4. Pipeline Products for Androgeneic alopecia - Overview
  5. Pipeline Products for Androgeneic alopecia - Comparative Analysis
  6. Androgeneic alopecia - Therapeutics under Development by Companies
  7. Androgeneic alopecia - Therapeutics under Investigation by Universities/Institutes
  8. Androgeneic alopecia - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Androgeneic alopecia - Products under Development by Companies
  13. Androgeneic alopecia - Products under Investigation by Universities/Institutes
  14. Androgeneic alopecia - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/nnfx4q/androgenic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Immune Disorders Drugs